Detail akcie Genmab online

Business Summary: Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Genmab A/S revenues increased 19% to $3.72B. Net income decreased 15% to $963M. Revenues reflect Royalties segment increase of 23% to $3.1B, Net product sales segment increase of 57% to $398M, Denmark segment increase of 16% to $3.33B, Japan segment increase of 75% to $213M. Net income was offset by Acquisition and integration related char increase from $43M to $185M (expense), Gain on marketable securities.